Lupin appoints Spiro Gavaris as President of U.S. Generics Business

Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business

Global pharma major Lupin Limited has announced the appointment of Spiro Gavaris as President U.S. Generics business.

As part of Lupin’s senior leadership team, Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business.

Commenting on the appointment, Vinita Gupta, CEO, Lupin said, “Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front. We are delighted to welcome him to our leadership team.”